PMGC Holdings (ELAB) Cash from Financing Activities (2022 - 2026)
PMGC Holdings (ELAB) posted Cash from Financing Activities of $14.4 million for Q1 2026, up 1441290700.0% sequentially from -$1.0 in Q4 2025, and up 389.7% YoY from $2.9 million in Q1 2025.
PMGC Holdings (ELAB) Cash from Financing Activities (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Cash from Financing Activities for 5 years, with the latest figure at $14.4 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 389.7% year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.6 million (up 151.86% YoY) and the FY2025 annual result came in at $10.1 million, up 49.71% from the prior year.
- Cash from Financing Activities advanced to $14.4 million in Q1 2026 per ELAB's latest filing, from -$1.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $14.4 million in Q1 2026 and troughed at -$2.3 billion in Q4 2022.
- A 5-year average of -$203.8 million and a median of $787500.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities slumped 100.0% in 2024, then surged 389.7% in 2026.
- Over 5 years, Cash from Financing Activities stood at -$2.3 billion in 2022, then surged by 100.23% to $5.2 million in 2023, then sank by 100.0% to -$1.0 in 2024, then changed by 0.0% to -$1.0 in 2025, then surged by 1441290700.0% to $14.4 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $14.4 million, -$1.0, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.41 Mn |
| Mar 31, 2026 | 14.41 Mn |
| Dec 31, 2025 | -1.00 |
| Dec 31, 2025 | -1.00 |
| Sep 30, 2025 | 5.71 Mn |
| Sep 30, 2025 | 5.71 Mn |
| Jun 30, 2025 | 1.47 Mn |
| Jun 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | 2.94 Mn |
| Mar 31, 2025 | 2.94 Mn |
| Dec 31, 2024 | -1.00 |
| Dec 31, 2024 | -1.00 |
| Dec 31, 2023 | 5.24 Mn |
| Dec 31, 2023 | 5.24 Mn |
| Sep 30, 2023 | 389,997.00 |
| Sep 30, 2023 | 389,997.00 |
| Jun 30, 2023 | 323,589.00 |
| Jun 30, 2023 | 323,589.00 |
| Mar 31, 2023 | 787,500.00 |
| Mar 31, 2023 | 787,500.00 |